Publications by authors named "David Ternant"

Claim this Profile
C
Cerebral diffusion of posaconazole in an experimental model of disseminated scedosporiosis.
Bénédicte Lelièvre, Charlotte Godon, Pierre Legras, Jérémie Riou, David Ternant

Biomed Pharmacother· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunoglobulin G Receptors (FcγR), in Addition to Target-Antigen and Neonatal Fc Receptor (FcRn), Influence Rituximab Pharmacokinetics.
David Ternant, Olivier Le Tilly, Guillaume Cartron, Céline Desvignes, Amina Bensalem

Clin Pharmacokinet· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality Assessment of Therapeutic Drug Monitoring Assays of Therapeutic Antibodies Across Europe: An Update.
James Bluett, Merita Rumano, María José Martínez Becerra, Floris Loeff, Mehmet Itik, David Ternant

Basic Clin Pharmacol Toxicol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of rituximab induction and maintenance regimens in anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: PK/PD modelling of ANCA and gammaglobulin levels in real-world patients.
Blaise Pasquiers, Benoit Blanchet, Xavier Puéchal, Xavier Declèves, Pascal Cohen, David Ternant

EBioMedicine· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicentric national phase II trial assessing TIslelizumab in monotherapy for patients with Hepatocellular Carcinoma Child-Pugh B and ALBI grade 1 or 2 liver function score: The UCGI 41 HESTIA TRIAL DESIGN AND PRELIMINARY SAFETY Data.
Héloïse Bourien, Xavier Adhoute, Boris Campillo-Gimenez, Mohamed Bouattour, Eric Assenat, David Ternant

Dig Liver Dis· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author's reply: "Personalized bevacizumab dosing in metastatic colorectal cancer: Statistical considerations for a phase III randomized trial".
Bruno Giraudeau, David Ternant, Thierry Lecomte

Dig Liver Dis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bevacizumab-based chemotherapy adaptive to pharmacokinetic of bevacizumab in first-line treatment of patients with unresectable metastatic colorectal cancer: A double-blind, multicenter, randomized phase III trial study (PHARBEVACOL trial).
Thierry Lecomte, Bruno Giraudeau, Jean-Marc Phelip, Christophe Tournigand, Michel Ducreux, David Ternant

Dig Liver Dis· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of mycophenolate in patients treated for interstitial lung disease (EVER-ILD study).
Yan-Min Xu, David Ternant, Martine Reynaud-Gaubert, Théodora Bejan-Angoulvant, Sylvain Marchand-Adam

Fundam Clin Pharmacol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eculizumab dose tapering should take into account the nonlinearity of its pharmacokinetics.
Olivier Le Tilly, Philippe Gatault, Saida Semlali, Rebecca Sberro-Soussan, Christophe Passot, David Ternant

Br J Clin Pharmacol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Confounding mitigation for the exposure-response relationship of bevacizumab in colorectal cancer patients.
Sarah Lobet, Morgane Caulet, Gilles Paintaud, Nicolas Azzopardi, Céline Desvignes, David Ternant

Br J Clin Pharmacol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective study to characterize adalimumab exposure in pediatric patients with rheumatic diseases.
Tatjana Welzel, Klervi Golhen, Andrew Atkinson, Verena Gotta, David Ternant

Pediatr Rheumatol Online J· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of the Clinical Course of Immune Thrombocytopenia in Children by Platelet Kinetics.
Julien Lejeune, Violette Raoult, Mathilde Dubrasquet, Romane Chauvin, Coralie Mallebranche, David Ternant

Hemasphere· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship Between Cetuximab Target-Mediated Pharmacokinetics and Progression-Free Survival in Metastatic Colorectal Cancer Patients.
Sarah Lobet, Gilles Paintaud, Nicolas Azzopardi, Christophe Passot, Morgane Caulet, David Ternant

Clin Pharmacokinet· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translation of Monoclonal Antibodies Pharmacokinetics from Animal to Human Using Physiologically Based Modeling in Open Systems Pharmacology (OSP) Suite: A Retrospective Analysis of Bevacizumab.
Blaise Pasquiers, Salih Benamara, Mathieu Felices, David Ternant, Xavier Declèves

Pharmaceutics· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study.
Guillaume Cartron, Emmanuel Bachy, Hervé Tilly, Nicolas Daguindau, Gian-Matteo Pica, David Ternant

J Clin Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to Biologic Drugs in Patients With Rheumatoid Arthritis and Antidrug Antibodies.
Samuel Bitoun, Signe Hässler, David Ternant, Natacha Szely, Aude Gleizes

JAMA Netw Open· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is CD25 blockade optimal in kidney transplant patients treated with basiliximab? A target-mediated drug disposition model.
Olivier Le Tilly, Philippe Gatault, Christophe Baron, Theodora Bejan-Angoulvant, Matthias Büchler, David Ternant

Br J Clin Pharmacol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML.
Emmanuel Gyan, Arnaud Pigneux, Mathilde Hunault, Pierre Peterlin, Martin Carré, David Ternant

Sci Rep· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Curcumin and NCLX inhibitors share anti-tumoral mechanisms in microsatellite-instability-driven colorectal cancer.
Maxime Guéguinou, Sajida Ibrahim, Jérôme Bourgeais, Alison Robert, Trayambak Pathak, David Ternant

Cell Mol Life Sci· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target-Mediated Drug Disposition.
Amina Bensalem, Guillaume Cartron, Ulrich Specks, Denis Mulleman, Emmanuel Gyan, David Ternant

Clin Pharmacokinet· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infliximab Treatment Does Not Lead to Full TNF-α Inhibition: A Target-Mediated Drug Disposition Model.
David Ternant, Marc Pfister, Olivier Le Tilly, Denis Mulleman, Laurence Picon

Clin Pharmacokinet· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Angiogenic factors could help us to define patients obtaining complete response with undetectable minimal residual disease in untreated CLL patients treated by FCR: results from the CLL2010FMP, a FILO study.
Anne Laure Gagez, Franciane Paul, Elina Alaterre, Valérie Gouilleux-Gruart, Edouard Tuaillon, David Ternant

Leuk Lymphoma· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment-A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model.
David Ternant, Olivier Le Tilly, Laurence Picon, Driffa Moussata, Christophe Passot

Pharmaceutics· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases.
Olivier Le Tilly, Gilles Paintaud, David Ternant

JAMA· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cross-Validation of a Multiplex LC-MS/MS Method for Assaying mAbs Plasma Levels in Patients with Cancer: A GPCO-UNICANCER Study.
Clémence Marin, Nihel Khoudour, Aurélien Millet, Dorothée Lebert, Pauline Bros, David Ternant

Pharmaceuticals (Basel)· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis